Autoantibodies to epithelial cells in patients on long-term therapy with leucocyte-derived interferon-alpha (IFN-alpha).
During routine screening for anti-nuclear antibodies, using rat liver tissue as substrate, a reactivity against bile duct epithelium was observed in sera from carcinoid tumour patients given human leucocyte-derived IFN-alpha (HuLe IFN-alpha). In a retrospective study, initiated by this observation, the development of serum antibodies to bile duct epithelium was observed in nine out of 12 patients with carcinoid tumours and in three out of 14 patients with hairy-cell leukaemia during their treatment with HuLe IFN-alpha. However, no bile duct reactivity was observed in sera from carcinoid or hairy-cell leukaemia in patients given recombinant IFN-alpha. When analysing the reactivity of positive sera against a panel of rat and human tissues, a uniform reactivity was observed against simple epithelial cells lining the gastrointestinal tract, pancreatic secretory ducts, fallopian tube, kidney tubuli, mesothelium and also against carcinoid tumour cells. The mechanisms promoting autoreactivity against this simple epithelial cell autoantigen is so far unknown. The cytoplasmic as well as the restricted staining pattern of simple epithelial cells may indicate autoreactivity against certain cytoskeletal intermediate filaments, such as cytokeratin 19, 18 and 8, known to be exclusively present in simple epithelial cells and tumours derived from them.
Karlsson-Parra
A
A
Department of Clinical Bacteriology, University of Uppsala, Sweden.
Burman
P
P
Hagberg
H
H
Oberg
K
K
Alm
G
G
Klareskog
L
L
Karlsson
F A
FA
D000818:Animals; D001323:Autoantibodies / Q000276:immunology*; D001652:Bile Ducts / Q000276:immunology; D002276:Carcinoid Tumor / Q000628:therapy*; D004848:Epithelium / Q000276:immunology*; D006801:Humans; D007124:Immunoenzyme Techniques; D007167:Immunotherapy; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D051381:Rats; D013997:Time Factors
D001323:Autoantibodies; D007370:Interferon Type I